arrow
L

Lyudmila Bazhenova

University of California San Diego
H指数:53
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer

临床因素和分子共改变影响接受奥希替尼一线治疗的EGFR突变非小细胞肺癌患者的预后

2025-09-070
PRE
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status

克唑替尼耐药的ALK阳性非小细胞肺癌患者中,brigatinib的活性根据ALK融合和突变状态。

2025-06-060
OAAI
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study

通过分子改变选择的实体瘤患者的sitratinib: Ib期研究的结果

2024-11-080
OAAI
Pooled efficacy and safety from 2 pivotal phase II trials of taletrectinib in patients (Pts) with advanced or metastatic ROS1+non-small cell lung cancer (NSCLC)

talentrectinib两项关键性II期试验中晚期或转移性ROS1+非小细胞肺癌(NSCLC)患者的合并有效性与安全性

2024-09-012
PRE
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation

具有KRASG12C突变的非小细胞肺癌中的Adagrasib

2022-07-14451
OA
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
2022-04-1159
OAAI
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2022-02-10112
OAAI
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer

曲妥珠单抗Deruxtecan在HER2-Mutant非小细胞肺癌中的应用

2022-01-20533
OA